LAVERDIA™-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526.
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Use only as Directed. It is a violation of Federal Law to use this product other than as directed in the labeling.
IMPORTANT SAFETY INFORMATION: LAVERDIA™-CA1 (verdinexor) is conditionally approved for the treatment of lymphoma in dogs. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA™-CA1. Children should not come into contact with the feces, urine, saliva, and vomit of treated dogs. View full product label for complete safety information. The most commonly reported adverse reactions in dogs include anorexia, weight loss, vomiting, diarrhea, and lethargy. Please see package insert or visit anivive.com for full prescribing information.